Swiss reject genetic protection bill:
This article was originally published in Clinica
Executive Summary
Swiss voters have rejected a proposal for a genetic protection bill which life science companies such as Roche and Novartis claim would have severely curtailed genetic research in Switzerland. According to press reports, the two companies spent around SFr35 million ($24.9 million) campaigning against the bill - other reports, however, put the figure at SFr8 million. The bill would have prohibited the patenting of products made using parts of genetically modified plants and animals, and the production and use of genetically modified animals.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.